Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Control BionicsASX:CBL +7.81% Cash Ratio is 1.41 as of Dec. 2025, which is 28% below its 10-year median of 1.96. The stock has 4 warning signs investors should review. Among 841 Medical Devices & Instruments companies, Control Bionics ranks better than 59.33% on this metric.
Control Bionics has a Cash Ratio of 1.41. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Control Bionics's Cash Ratio or its related term are showing as below:
ASX:CBL'
s Cash Ratio Range Over the Past 10 Years
Min: 0.23 Med: 1.96 Max: 42.85
Current: 1.41
During the past 6 years, Control Bionics's highest Cash Ratio was 42.85. The lowest was 0.23. And the median was 1.96.
ASX:CBL's Cash Ratio is ranked better than 59.33% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 0.97
vs ASX:CBL: 1.41
Control Bionics (ASX:CBL) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Control Bionics Cash Ratio Related Terms
Control Bionics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Control Bionics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Control Bionics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Control Bionics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Control Bionics (ASX:CBL) has a Cash Ratio of 1.41 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Control Bionics and its competitors. This is 28% below median its historical median of 1.96. Over the past decade, Control Bionics' Cash Ratio has ranged from 0.23 to 42.85. According to the industry distribution chart, Control Bionics ranks #342 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 40.7%.
Is Control Bionics' Cash Ratio too high?
Control Bionics' current Cash Ratio of 1.41 is 28% below median its 10-year median of 1.96. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 42.85. The Medical Devices & Instruments industry median Cash Ratio is 0.97. Control Bionics' value of 1.41 is 45.4% above this industry median. Based on the distribution chart, Control Bionics ranks #342 out of 841 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Control Bionics' Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #342 out of 841 companies for Cash Ratio. This puts Control Bionics in the upper half of its industry. The industry median Cash Ratio is 0.97. Control Bionics' value of 1.41 is 45.4% above this benchmark. Historically, Control Bionics' own Cash Ratio has ranged from 0.23 to 42.85 over the past decade. While the company's 10-year median is 1.96 vs. the industry median of 0.97, Control Bionics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.97, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Control Bionics's current Cash Ratio of 1.41 is 45.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current Cash Ratio is 1.41, which is 28% below median its own 10-year median of 1.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.07 — trading 130% above its estimated fair value. The current Cash Ratio is 1.41, which is 28% below median its 10-year median of 1.96 and 45.4% above the Medical Devices & Instruments industry median of 0.97. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current Cash Ratio is 1.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 
